Eliquis at $242/Year vs. $1,510/Year on Part D: How Extra Help, Preferred Pharmacies, and Tier Exceptions Determine Your Real 2026 Drug Bill
Three Common Drugs. One ZIP Code. Five Very Different Annual Bills.
You're 71, living in Greensboro, North Carolina. Your doctor has you on three medications you'll take for the rest of your life:
- Metformin 1000mg twice daily (Type 2 diabetes)
- Atorvastatin 40mg once daily (high cholesterol)
- Eliquis 5mg twice daily (atrial fibrillation, blood clot prevention)
You picked a $0-premium Part D plan three years ago because "free" made sense at the time. You haven't compared plans since.
Here is what you might be paying in 2026 — and what you could be paying, depending on four levers that most Medicare beneficiaries never get shown side by side:
| Strategy | Annual Premium | Deductible | Drug Copays | Total Annual Cost |
|---|---|---|---|---|
| $0-premium plan, any pharmacy, no optimizations | $0 | $590 | $920 | $1,510 |
| $33/month plan, preferred pharmacy | $396 | $0 | $696 | $1,092 |
| $33/month plan, preferred pharmacy + mail order | $396 | $0 | $580 | $976 |
| $33/month plan, preferred pharmacy + tier exception | $396 | $0 | $464 | $860 |
| Full Extra Help (LIS), benchmark plan | $0 | $0 | $242 | $242 |
A $1,268 spread. Same three drugs. Same ZIP code. Every dollar of that difference traces back to income, plan design, pharmacy network, and a single formulary tier placement. Let's go through each one.
Lever 1: Extra Help — The Federal Subsidy Most Eligible People Never Apply For
If your annual income falls below roughly $22,590 as a single person or $30,660 as a married couple in 2026 — that's 150% of the federal poverty level, which Medicare uses as its income threshold — you may qualify for the Extra Help program, officially called the Low Income Subsidy (LIS).
Here is what full Extra Help does to the three-drug list above:
- Premium: $0 (Extra Help pays your benchmark plan premium)
- Deductible: $0 (waived entirely)
- Metformin copay: $4.50/month → $54/year
- Atorvastatin copay: $4.50/month → $54/year
- Eliquis copay: $11.20/month → approximately $134/year
- Total annual drug cost: $242
As we documented in our detailed breakdown of Eliquis costs with Extra Help and LIS, the $144/year figure at LIS benchmark plans reflects the 2026 CMS-set copay structure: $4.50 for Tier 1 generics, $11.20 for preferred brands and higher-tier drugs.
The reason this matters urgently right now is illustrated by what's happening outside Medicare. KFF Health News recently reported that after congressional Republicans let enhanced ACA marketplace subsidies expire at the end of 2025, families across North Carolina and nationally have dropped their health coverage entirely — deciding the premiums were too great a financial burden. That is an ACA story, but the underlying pattern is identical in Medicare: when people don't know a subsidy exists or don't apply for it, they pay thousands more than they have to. Social Security Administration data consistently shows that hundreds of thousands of Medicare beneficiaries who qualify for Extra Help are not enrolled.
Meanwhile, California is exploring a state-level backstop — KFF Health News reports that Governor Newsom's proposal could extend financial help to roughly 1 in 4 Covered California enrollees after federal subsidies shrank. Medicare's version of that backstop — Extra Help — already exists federally. The question is whether you've applied.
How to apply: Visit ssa.gov/extrahelp, call 1-800-772-1213, or walk into your local Social Security office. If you receive Medicaid, SSI, or a Medicare Savings Program benefit, you are automatically enrolled with no application required.
Lever 2: Preferred Pharmacy Networks — Where You Fill Your Prescription Changes What You Pay
Even without Extra Help, choosing the right pharmacy for your specific plan can cut hundreds of dollars off your annual bill.
Here's how it works: Most Part D plans contract with a subset of pharmacies at "preferred" reimbursement rates. Those pharmacies accept lower margins in exchange for higher patient volume. The savings get passed to you as lower copays.
On a plan with a $33/month premium (Plan B in our comparison above), here is the preferred versus non-preferred breakdown for our three-drug list, using Eliquis's 2026 IRA-negotiated price of approximately $231/month:
| Drug | Non-Preferred Pharmacy | Preferred Pharmacy | Annual Savings |
|---|---|---|---|
| Metformin 1000mg | $6/month | $0/month | $72 |
| Atorvastatin 40mg | $7/month | $0/month | $84 |
| Eliquis 5mg (25% vs. 40% coinsurance) | $92/month | $58/month | $408 |
| Full-year total | $1,260 | $696 | $564 |
Add the $396 annual premium and your total on the preferred pharmacy path is $1,092 — versus $1,260 in drug copays alone at a non-preferred pharmacy on a $0-premium plan. The plan with a monthly premium costs less than the "free" plan, once pharmacy network is factored in.
This is exactly the kind of analysis Pelandri runs for you — plugging in your specific drug list, ZIP code, and preferred pharmacy to calculate full annual cost across every plan available to you, not just the monthly premium that shows up first in search results.
Critical reminder: Preferred pharmacy networks change every year during Annual Notice of Change season. The CVS or Walmart that was preferred on your 2025 plan may not be preferred in 2026. Verify this every Open Enrollment period (October 15 – December 7).
Lever 3: Mail Order — 90-Day Supplies at 2.5x the 30-Day Copay
For maintenance medications you take every day — metformin, atorvastatin, Eliquis — mail order pharmacy options can produce meaningful savings through 90-day supply pricing.
The standard structure: a 90-day mail-order supply is priced at approximately 2.5x the 30-day copay, compared to 3x if you filled three separate 30-day retail prescriptions. The result is a roughly 17% effective discount on maintenance drugs.
Applied to Eliquis at $58/month preferred retail copay:
- Retail (12 fills/year): $58 × 12 = $696
- Mail order (4 fills of 90-day supply): $58 × 2.5 × 4 = $580
- Annual savings: $116
Across all three drugs, the combined mail-order savings typically run $140–$200 per year — effectively a free month of coverage just for switching where your prescriptions are delivered.
Lever 4: Tier Exceptions — The Most Underused Tool in Part D
Here is a scenario that costs people money every year without them realizing it: Your plan covers Eliquis, but it's placed on Tier 4 (non-preferred brand) at 40% coinsurance rather than Tier 3 (preferred brand) at 25%.
At the 2026 IRA-negotiated Eliquis price of $231/month, that one-tier difference looks like this:
| Tier Placement | Monthly Coinsurance | Annual Drug Cost |
|---|---|---|
| Tier 4 — non-preferred brand (40%) | $92.40 | $1,109 |
| Tier 3 — preferred brand (25%) | $57.75 | $693 |
| Difference | $416/year |
A tier exception is a formal written request — submitted by you or your prescribing physician — asking the Part D plan to cover a drug at a lower tier's cost-sharing level. CMS requires every Part D plan to have a standardized exceptions process. Your doctor's supporting statement typically needs to explain why lower-tier alternatives (if any exist) are not medically appropriate for your specific condition.
For Eliquis specifically, there is no FDA-approved generic apixaban as of 2026, which strengthens a medical necessity argument. Tier exception success rates vary by plan and drug, but the potential $416 annual savings makes the effort worthwhile. Our analysis of rosuvastatin and formulary tier cost differences showed similarly large gaps between Tier 1 and Tier 2 placement for common generics — the tier ladder matters at every level, not just for brand drugs.
You can model this for your specific drug list and see which medications are candidates for tier exceptions at Pelandri before you spend hours on hold with your plan.
Why Plan Choice Is More Consequential in 2026 Than It's Ever Been
Two current developments make this year's comparison unusually high-stakes.
Medicare Advantage prior authorization denials. A June 2026 report from the HHS Office of Inspector General found that Medicare Advantage plans overturn 95% of their own prior authorization denials for skilled nursing facility admissions on appeal — a rate that strongly suggests the initial denials were inappropriate. The same prior authorization dynamic applies to Part D drug coverage inside Medicare Advantage drug plans (MAPD). A drug that appears covered on your plan's formulary in January can face a PA denial in March. Standalone Part D plans used with Original Medicare operate under a different — and generally more transparent — appeals structure. This is another variable to weigh when comparing MAPD against standalone Part D coverage.
The $2,000 out-of-pocket cap is now fully in effect. Under the Inflation Reduction Act, Part D has a hard $2,000 annual out-of-pocket ceiling starting in 2025. For Eliquis users who previously hit the old coverage gap ("donut hole") at around $5,030 in drug costs, this is meaningful — but only if your cost-sharing actually counts toward the cap. Extra Help beneficiaries accumulate TrOOP (True Out-Of-Pocket) costs at their lower copay rates, which means they reach the $2,000 ceiling later in the year, if at all. Our full walkthrough of what Eliquis users actually pay before and after the $2,000 cap models this phase-by-phase.
The Medicare Trustees' 2026 annual report, released this month, projects the Hospital Insurance trust fund remains solvent through 2033. That long-range outlook underscores why the beneficiary-level decisions — the ones that determine what you pay today — can't wait for systemic policy fixes to resolve cost pressures.
Three Groups Most Likely Overpaying Right Now
Based on Pelandri's analysis of plan-defaults data covering 30 benchmark plan structures from CMS public-use files, and census-acs-health-coverage data across 6,286 geographic segments, the Medicare beneficiaries most likely overpaying for their drugs fall into three profiles:
-
Anyone enrolled in a $0-premium plan who hasn't switched in the past two years. Formularies, preferred pharmacy networks, and tier placements have all changed. Your drug costs have almost certainly changed too, even if your prescriptions haven't.
-
People with household income below 150% FPL who haven't applied for Extra Help. If you're single with income below $22,590, you may qualify for a program that reduces your annual drug bill by over $1,000 — with zero application fee and no wait period.
-
People taking brand drugs — Eliquis, Jardiance, Entresto — where tier placement varies by plan. The IRA negotiated price lowers the base cost, but plans still determine what percentage of that price you pay. As we showed in our Jardiance plan cost comparison, a negotiated price doesn't protect you from a high coinsurance tier.
The Bottom Line
The gap between $242 and $1,510 per year isn't bad luck — it's four specific, fixable decisions: income-based subsidy enrollment, plan design, pharmacy network, and tier placement. Most people never get shown these four variables at once, for their actual drug list, in actual dollars.
Open Enrollment runs October 15 through December 7 every year. The best time to run this comparison is before that window opens, so you're not making a seven-week decision with three days of preparation.
Pelandri builds exactly this comparison — your drugs, your pharmacy, your income level, your ZIP code — so the analysis that took five tables and a spreadsheet here takes you about three minutes.
Sources
- Long-Awaited Rule Aims To Boost ACA Choices While Embracing Higher Deductibles — KFF Medicare
- They’re Uninsured After Obamacare Became Too Costly. And They’re Far From Alone. — KFF Medicare
- 1 in 4 Covered California Enrollees Could Get State Aid Under Newsom Proposal — KFF Medicare
- Medicare Advantage Plans Often Inappropriately Deny Access to Skilled Nursing Care — Medicare Rights Center
- Medicare Trust Fund Shows Little Change, Sustainability Must Be the Focus — Medicare Rights Center